Meta-Analysis

Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients

  1. J. Schreiber1,†,
  2. C. Moreno1,†,
  3. B. Garcia Garcia2,
  4. A. Louvet3,4,
  5. E. Trepo1,
  6. J. Henrion2,
  7. D. Thabut5,
  8. P. Mathurin3,4,
  9. P. Deltenre2,3,*

Article first published online: 29 JUN 2012

DOI: 10.1111/j.1365-2036.2012.05197.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 36, Issue 4, pages 353–362, August 2012

Additional Information

How to Cite

Schreiber, J., Moreno, C., Garcia, B. G., Louvet, A., Trepo, E., Henrion, J., Thabut, D., Mathurin, P. and Deltenre, P. (2012), Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Alimentary Pharmacology & Therapeutics, 36: 353–362. doi: 10.1111/j.1365-2036.2012.05197.x

Author Information

  1. 1

    Service de Gastroentérologie et d'Hépatopancréatologie, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium

  2. 2

    Service d'Hépato-Gastroentérologie, Hôpital de Jolimont, Haine-Saint-Paul, Belgium

  3. 3

    Service d'Hépato-Gastroentérologie, Hôpital Huriez, CHRU Lille, Lille, France

  4. 4

    INSERM U995, CHRU Lille, Lille, France

  5. 5

    Service d'Hépato-Gastroentérologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France

  1. †

    Equal contribution.

*Correspondence to:
Dr P. Deltenre, Service d'Hépato-Gastroentérologie, Hôpital de Jolimont, 159, rue Ferrer, 7100, Haine-Saint-Paul, Belgium. E-mail: pierre.deltenre@skynet.be

  1. †

    Equal contribution.

  2. As part of AP&T's peer-review process, a technical check of this meta-analysis was performed by Dr P. Collins.

Publication History

  1. Issue published online: 16 JUL 2012
  2. Article first published online: 29 JUN 2012
  3. Manuscript Accepted: 5 JUN 2012
  4. Manuscript Revised: 18 MAY 2012
  5. Manuscript Revised: 6 MAR 2012
  6. Manuscript Received: 24 JAN 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (219K)

Summary

Background

Recent studies suggested that IL28B polymorphisms may affect rapid and sustained virological response rates in HCV patients infected with genotype 2 or 3.

Aim

To assess the role of IL28B polymorphisms on the virological response in HCV-2 and -3 patients.

Methods

We performed meta-analysis of studies evaluating the impact of rs12979860 and rs8099917 polymorphisms on rapid and sustained virological response in HCV-2 or -3 patients.

Results

Twenty-three studies involving 3042 patients were included. The first meta-analysis evaluated the impact of rs12979860 polymorphism and included 1963 patients. When compared with rs12979860 CT/TT patients, CC patients had a higher rapid virological response rate (mean difference: 12.9%, 95% CI: 6.5–19.4%, P < 0.001) and a higher sustained virological response rate (mean difference: 4.9%, 95% CI: 0.1–9.8%, P = 0.046). The second meta-analysis evaluated the impact of rs8099917 polymorphism and included 2246 patients. When compared with rs8099917 TG/GG patients, TT patients had a higher rapid virological response rate (mean difference: 14.8%, 95% CI: 7.2–22.4%, P < 0.001) and a higher sustained virological response rate (mean difference: 5.5%, 95% CI: 0.4–10.6%, P = 0.033). When considering only patients treated for 24 weeks, results were unchanged. No potential sources of between-study heterogeneity were identified.

Conclusions

Favourable IL28B polymorphisms are associated with higher rapid and sustained virological response rates in HCV-2 and -3 patients. However, as the impact on a sustained response is very limited, it is unlikely that IL28B polymorphisms provide additional predictive value when considering other predictors of a sustained response.

View Full Article with Supporting Information (HTML) Get PDF (219K)